Acoramidis bulk supplier for pharma manufacturers

Acoramidis 356 mg Suppliers & Bulk Manufacturers

Available Forms: Tablet

Available Strengths: 356 mg

Reference Brands: Attruby(USA/EU), Beyonttra (UK)

Acoramidis is a first-in-class oral transthyretin (TTR) stabilizer designed for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) in adults. This rare and progressive heart condition can lead to heart failure and increased risk of cardiovascular death. Acoramidis works by stabilizing the TTR protein, preventing amyloid deposits in the heart, thereby reducing cardiovascular death and related hospitalizations.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Acoramidis — third party manufacturing & bulk supply

Acoramidis 356 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Acoramidis is supplied as Tablet — an oral solid dosage form, so the indicative MOQ is 200,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Acoramidis listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Acoramidis →

Back to Listing

Frequently Asked Questions

Acoramidis is listed as Tablet in 356 mg. Further strengths and pack presentations are confirmed with the manufacturer at RFQ stage.

Acoramidis is referenced against Attruby(USA/EU), Beyonttra (UK). Reference brands are shown for identification only and remain the property of their respective trademark owners.